Camlin Fine Sciences Q3 FY'26 Earnings Call Transcript Released
Camlin Fine Sciences reported Q3 FY'26 revenue of ₹572 crores. The company plans to leverage tariff changes for higher Vanillin realizations. Blends business grew 11%, aided by Vinpai acquisition. Management projects FY'27 gross margins at 46-47% and EBITDA margins at 12-14%. A fire incident in Brazil and liquidation of European entity were also discussed.
The announcement provides detailed financial performance for the quarter, outlook for the next fiscal year, and discusses significant operational events like a fire incident and corporate restructuring. These details are material for investors to assess the company's performance and future prospects.
The announcement is a transcript of a conference call discussing financial results and operational updates. While there are positive aspects like revenue growth in Blends and future margin projections, there are also challenges mentioned such as a tepid quarter, impact of tariffs, a fire incident, and liquidation of an entity. The overall tone is factual and informative, reflecting a mix of positive and negative developments.
Camlin Fine Sciences Limited has released the transcript of its conference call held on February 13, 2026, discussing the un-audited financial results for the quarter and nine months ended December 31, 2025. The management, including Chairman & Managing Director Mr. Ashish Dandekar, Managing Director Mr. Nirmal Momaya, and CFO Mr. Santosh Parab, reviewed the financial performance and addressed investor queries. The company reported a tepid quarter with turnover of ₹572 crores, a 6% increase year-on-year. Vanillin sales were impacted by tariff changes, with a planned delay in sales to capitalize on future price increases. Straights business saw a decline due to falling prices and increased competition, while Blends business grew by 11% year-on-year, boosted by the acquisition of French company Vinpai Limited. EBITDA expectations were moderated due to strategic Vanillin sales management. The company also disclosed a fire incident at a blending unit in Brazil, which resulted in the loss of stock and a warehouse, though adequate insurance is in place. The liquidation process for the European entity is scheduled for February 26, with the business to be shifted to other European companies. Exceptional items in the quarter included acquisition-related costs for Vinpai and a provision for a doubtful advance term loan. The company provided guidance for FY'27, expecting gross margins to improve to 46%-47% and EBITDA margins to reach 12%-14%, driven by higher Vanillin realizations and growth in the Blends business. Discussions also covered the integration of Vinpai and Vitafor, future volume guidance for Vanillin, and the impact of tariff changes on pricing in the US and Europe.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.